Vemurafenib Inhibits Enterovirus A71 Genome Replication and Virus Assembly
Citations Over TimeTop 20% of 2022 papers
Abstract
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot, and mouth disease (HFMD), which may be occasionally associated with severe neurological complications. There is currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation, and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late-stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentrations. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.
Related Papers
- → The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study(2018)5 cited
- → The combination of vemurafenib and cobimetinib in advanced melanoma(2016)3 cited
- → Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth(2019)4 cited
- Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.(2015)
- → Experiences of treating melanoma with vemurafenib at our institution and a discussion of its adverse effects(2016)